DexCom’s Q2 earnings soared with a 13% revenue jump, fueled by global demand for their CGMs and strong organic growth. They unveiled an ambitious five-year plan, including a $1B stock buyback, and are pushing to become the gold standard in glucose sensing. New trial data shows dramatic A1C improvements for non-insulin type two diabetics — even better than prior studies — paving the way for broader insurance coverage. Partnering with CVS, they’ve proven CGM use cuts hospitalizations by 66%, now covered by top PBMs and preparing to submit to CMS. Meanwhile, their Stelo app brings AI-powered insights, a Smart Basal feature simplifies insulin, and the G7 15-day sensor is already cleared in Canada — all accelerating global access and market dominance.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
